NCT07013110View on ClinicalTrials.gov

An Artificial Intelligence-powered Approach to Precision Immunotherapy of Human Arthritis

PHASE2RecruitingINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

June 18, 2025

Primary Completion Date

November 30, 2028

Study Completion Date

November 30, 2028

Conditions
Rheumatoid Arthritis (RA)Rheumatology
Interventions
DRUG

dnaJP1

The study drug is dnaJP1 peptide. It is a manmade short protein that can be taken easily as a pill. dnaJP1 works to restore the body's immune tolerance by improving its ability to self-adjust - helps to restore the immune system and improve controls on inflammation that has been lost.

DRUG

Placebo

This is the control.

Trial Locations (1)

169856

RECRUITING

Singapore General Hospital, Singapore

All Listed Sponsors
collaborator

Singapore General Hospital

OTHER

lead

Prof Salvatore Albani

OTHER